NASDAQ:SAGE - SAGE Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$155.33 -2.84 (-1.80 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$155.33
Today's Range$153.0750 - $159.62
52-Week Range$59.57 - $195.97
Volume277,730 shs
Average Volume529,865 shs
Market Capitalization$7.25 billion
P/E Ratio-21.91
Dividend YieldN/A
Beta3.05

About SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics logoSage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which has completed Phase II clinical trials for the treatment of PPD, major depressive disorders, bipolar depression, Parkinson's disease, and sleep disorders; and SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of depression, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, Huntington's disease, and neuropathic pain. In addition, its product pipeline comprises SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and product pipeline that are in preclinical stage includes SAGE-689 and SAGE-105 novel GABAA receptor modulators The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Debt-to-Equity RatioN/A
Current Ratio28.92
Quick Ratio28.92

Price-To-Earnings

Trailing P/E Ratio-21.91
Forward P/E Ratio-18.43
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$22.77 per share
Price / Book6.82

Profitability

EPS (Most Recent Fiscal Year)($7.09)
Net Income$-270,120,000.00
Net MarginsN/A
Return on Equity-57.73%
Return on Assets-52.95%

Miscellaneous

Employees257
Outstanding Shares46,520,000

SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) posted its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating the consensus estimate of ($1.84) by $0.16. During the same quarter in the previous year, the business earned ($1.52) EPS. View SAGE Therapeutics' Earnings History.

What price target have analysts set for SAGE?

15 analysts have issued 12 month price targets for SAGE Therapeutics' stock. Their predictions range from $86.00 to $280.00. On average, they expect SAGE Therapeutics' share price to reach $185.20 in the next year. View Analyst Ratings for SAGE Therapeutics.

What are Wall Street analysts saying about SAGE Therapeutics stock?

Here are some recent quotes from research analysts about SAGE Therapeutics stock:
  • 1. Canaccord Genuity analysts commented, "We like the setup heading into a catalyst-rich 2H18/2019E We are updating our model after SAGE reported its 1Q18 and provided a corporate update today (5/3). With its first product, brexanolone IV for postpartum depression (PPD), filed with potential commercialization in 1H19, and a robust pipeline of neuro- focused assets led by SAGE-217, our BUY thesis on the stock remains unchanged. In short, we like SAGE’s pipeline that targets several large central nervous system (CNS) indications where the unmet need is high (e.g., major depressive disorder, PPD, Parkinson’s, etc.) and the scarcity value that comes with robust/ripening CNS platforms. With the stock having pulled back ~25% since its 52-week high on 1/31/18, we like the setup heading into a catalyst-rich 2H18/2019E. Our DCF-based price target remains unchanged at $210." (5/3/2018)
  • 2. Cowen Inc analysts commented, "We note that neither Mylan nor Biocon would comment on Neulasta’s updated timing. We spoke with a manufacturing consultant who believed that biosimilar Neulasta would not receive an approval until the Form 483 issues were resolved. We expect an update on Mylan’s earnings call on Wednesday, 5/9/18. Biocon Form 483: Biocon announced yesterday (5/1/18) that the FDA issued a Form 483 with 7 observations relating to the company’s Bangalore, India site. As a reminder, MYL has a partnership with Biocon to produce biosimilars Neulasta/Herceptin out of the same facility. The TAD for biosimilar Neulasta is on 6/4/18. Biocon noted that the observations were largely procedural and aimed at continuous improvement. Further, the company indicated that it would respond to the FDA well within" the typical 15 day response period." (5/3/2018)
  • 3. Needham & Company LLC analysts commented, "FY 2017 results were generally in line with expectations. We note that ‘217 Phase 2 PPD data are now expected in 4Q18 (was 2Q). The additional delay (previously moved from 1Q18 to 2Q18) is reportedly due to an increase in target enrollment (now ~140 PPD patients). We still anticipate a positive outcome and think running a full-scale trial makes sense given prior supportive data. With the robust size and design of the study, we believe it could serve as a registration trial and help streamline ‘217 time to market. Sage still plans to conduct several additional well powered trials (insomnia, bipolar depression, PD tremor) with oral ‘217 this year. Further evaluation of ‘217 for MDD, including potential initiation of pivotal Phase 3 development is also anticipated in 2018 (unch). BUY." (2/23/2018)

Who are some of SAGE Therapeutics' key competitors?

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the folowing people:
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 47)
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 65)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 56)
  • Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 57)

Has SAGE Therapeutics been receiving favorable news coverage?

Media stories about SAGE stock have been trending very positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. SAGE Therapeutics earned a media sentiment score of 0.50 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 41.79 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.11%), OppenheimerFunds Inc. (3.36%), BB Biotech AG (2.15%), Palo Alto Investors LP (1.76%), JPMorgan Chase & Co. (1.55%) and Eagle Asset Management Inc. (1.32%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

Which major investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Oak Ridge Investments LLC, JPMorgan Chase & Co., DekaBank Deutsche Girozentrale, BB Biotech AG, Element Capital Management LLC, Eventide Asset Management LLC and Franklin Resources Inc.. Company insiders that have sold SAGE Therapeutics company stock in the last year include Albert Robichaud, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

Which major investors are buying SAGE Therapeutics stock?

SAGE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Victory Capital Management Inc., Point72 Asset Management L.P., Bamco Inc. NY, Hood River Capital Management LLC, OppenheimerFunds Inc. and DAFNA Capital Management LLC. View Insider Buying and Selling for SAGE Therapeutics.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $155.33.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $7.25 billion. The biopharmaceutical company earns $-270,120,000.00 in net income (profit) each year or ($7.09) on an earnings per share basis. SAGE Therapeutics employs 257 workers across the globe.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (SAGE)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  547
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SAGE Therapeutics (NASDAQ:SAGE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
15 Wall Street analysts have issued ratings and price targets for SAGE Therapeutics in the last 12 months. Their average twelve-month price target is $185.20, suggesting that the stock has a possible upside of 19.23%. The high price target for SAGE is $280.00 and the low price target for SAGE is $86.00. There are currently 1 sell rating, 1 hold rating and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.793.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $185.20$185.20$171.2143$105.7143
Price Target Upside: 19.23% upside18.54% upside10.18% upside23.40% upside

SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History

Price Target History for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018Canaccord GenuityReiterated RatingBuy$210.00LowView Rating Details
5/3/2018CowenReiterated RatingBuyLowView Rating Details
2/28/2018SunTrust BanksBoost Price TargetBuy$203.00LowView Rating Details
2/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$225.00LowView Rating Details
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00LowView Rating Details
1/10/2018JPMorgan Chase & Co.Reiterated RatingBuyHighView Rating Details
12/8/2017Stifel NicolausReiterated RatingBuy$198.00LowView Rating Details
12/7/2017Raymond JamesReiterated RatingBuy$206.00HighView Rating Details
12/7/2017Leerink SwannBoost Price Target$123.00 ➝ $246.00HighView Rating Details
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00HighView Rating Details
12/7/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Sell$137.00 ➝ $280.00HighView Rating Details
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 ➝ $101.00N/AView Rating Details
11/10/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $140.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy ➝ Buy$87.00N/AView Rating Details
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00HighView Rating Details
12/14/2016UBSUpgradeOutperform ➝ Strong-BuyN/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

SAGE Therapeutics (NASDAQ:SAGE) Earnings History and Estimates Chart

Earnings by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ:SAGE) Earnings Estimates

2018 EPS Consensus Estimate: ($7.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.76)($1.75)($1.76)
Q2 20182($1.87)($1.75)($1.81)
Q3 20183($2.02)($1.91)($1.95)
Q4 20183($2.16)($1.95)($2.07)

SAGE Therapeutics (NASDAQ SAGE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($1.84)($1.68)ViewN/AView Earnings Details
2/22/2018Q4 2017($1.9810)($1.75)ViewN/AView Earnings Details
11/2/2017Q3 2017($1.9830)($1.97)ViewN/AView Earnings Details
8/3/2017Q2 2017($1.63)($1.88)ViewListenView Earnings Details
5/9/2017Q1 2017($1.6080)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
11/5/2015Q3 2015($0.85)($0.84)ViewN/AView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

SAGE Therapeutics (NASDAQ:SAGE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

SAGE Therapeutics (NASDAQ SAGE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Insider Trading History for SAGE Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ SAGE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/8/2018James M FratesDirectorSell7,000$154.00$1,078,000.0012,000View SEC Filing  
4/25/2018Kimi IguchiCFOSell28,153$142.73$4,018,277.6963,499View SEC Filing  
4/23/2018Kimi IguchiCFOSell12,135$144.48$1,753,264.8063,499View SEC Filing  
4/18/2018Kevin P StarrDirectorSell59,000$168.85$9,962,150.00326,817View SEC Filing  
3/6/2018Steven M PaulDirectorSell58,139$172.00$9,999,908.00632,712View SEC Filing  
1/10/2018Stephen KanesInsiderSell44,000$177.18$7,795,920.0046,348View SEC Filing  
12/21/2017Jeffrey M JonasCEOSell210,247$157.45$33,103,390.15211,473View SEC Filing  
12/14/2017Albert RobichaudInsiderSell60,000$159.43$9,565,800.00152,759View SEC Filing  
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.0075,739View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.0079,739View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.0081,239View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00140,222View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.0083,739View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.0065,227View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.0025,948View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00162,222View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.0046,948View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.0084,563View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00683,650View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.0031,948View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SAGE Therapeutics (NASDAQ SAGE) News Headlines

Source:
DateHeadline
Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor StudySage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study
www.thestreet.com - May 25 at 5:16 PM
Here's Why Marinus Pharmaceuticals Rose as Much as 18.4% TodayHere's Why Marinus Pharmaceuticals Rose as Much as 18.4% Today
finance.yahoo.com - May 24 at 5:08 PM
SAGE Therapeutics Inc (SAGE) Given Consensus Recommendation of "Buy" by BrokeragesSAGE Therapeutics Inc (SAGE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 3:28 AM
Sage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions ConferenceSage Therapeutics to Present at Bernstein’s 34th Annual Strategic Decisions Conference
finance.yahoo.com - May 23 at 8:42 AM
Albireo (ALBO) & SAGE Therapeutics (SAGE) Financial ComparisonAlbireo (ALBO) & SAGE Therapeutics (SAGE) Financial Comparison
www.americanbankingnews.com - May 21 at 3:17 PM
Zacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$1.93 Per ShareZacks: Brokerages Anticipate SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$1.93 Per Share
www.americanbankingnews.com - May 19 at 3:22 AM
SAGE Therapeutics (SAGE) Lifted to Hold at BidaskClubSAGE Therapeutics (SAGE) Lifted to Hold at BidaskClub
www.americanbankingnews.com - May 15 at 12:36 AM
Insider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 7,000 Shares of StockInsider Selling: SAGE Therapeutics Inc (SAGE) Director Sells 7,000 Shares of Stock
www.americanbankingnews.com - May 8 at 7:39 PM
Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care ConferenceSage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 8 at 8:49 AM
Edited Transcript of SAGE earnings conference call or presentation 3-May-18 12:00pm GMTEdited Transcript of SAGE earnings conference call or presentation 3-May-18 12:00pm GMT
finance.yahoo.com - May 4 at 8:48 AM
SAGE Therapeutics (SAGE) "Buy" Rating Reaffirmed at CowenSAGE Therapeutics' (SAGE) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 4 at 12:01 AM
SAGE Therapeutics (SAGE) Given a $210.00 Price Target at Canaccord GenuitySAGE Therapeutics (SAGE) Given a $210.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - May 3 at 10:55 PM
Lucky Seven: An Introduction To My Top Biotechnology PicksLucky Seven: An Introduction To My Top Biotechnology Picks
seekingalpha.com - May 3 at 4:57 PM
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress ...Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress ...
www.businesswire.com - May 3 at 4:57 PM
BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68
www.reuters.com - May 3 at 4:57 PM
Sage Therapeutics 2018 Q1 - Results - Earnings Call SlidesSage Therapeutics 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 4:57 PM
SAGE Therapeutics (SAGE) Issues  Earnings Results, Beats Expectations By $0.16 EPSSAGE Therapeutics (SAGE) Issues Earnings Results, Beats Expectations By $0.16 EPS
www.americanbankingnews.com - May 3 at 2:54 PM
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch ReadinessSage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness
finance.yahoo.com - May 3 at 8:45 AM
SAGE Therapeutics (SAGE) Scheduled to Post Earnings on ThursdaySAGE Therapeutics (SAGE) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:15 PM
SAGE Therapeutics (SAGE) Upgraded to "Strong-Buy" at ValuEngineSAGE Therapeutics (SAGE) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 2 at 6:30 PM
 Brokerages Expect SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$1.85 Per Share Brokerages Expect SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$1.85 Per Share
www.americanbankingnews.com - May 1 at 1:23 PM
Ovid Therapeutics: Beaten-Down IPO With Upcoming 2018 CatalystsOvid Therapeutics: Beaten-Down IPO With Upcoming 2018 Catalysts
seekingalpha.com - May 1 at 8:54 AM
SAGE Therapeutics Inc (SAGE) Given Average Rating of "Buy" by AnalystsSAGE Therapeutics Inc (SAGE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 3:24 AM
CNBC's 2018 Stock Draft Round 3CNBC's 2018 Stock Draft Round 3
finance.yahoo.com - April 27 at 9:12 AM
SAGE Therapeutics Inc (SAGE) CFO Kimi Iguchi Sells 12,135 SharesSAGE Therapeutics Inc (SAGE) CFO Kimi Iguchi Sells 12,135 Shares
www.americanbankingnews.com - April 25 at 7:10 PM
Kimi Iguchi Sells 28,153 Shares of SAGE Therapeutics Inc (SAGE) StockKimi Iguchi Sells 28,153 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - April 25 at 7:10 PM
Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018
finance.yahoo.com - April 24 at 8:47 AM
Sage files U.S. marketing application for PPD med brexanolone; shares up 1% premarketSage files U.S. marketing application for PPD med brexanolone; shares up 1% premarket
seekingalpha.com - April 23 at 8:38 AM
Sage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum DepressionSage Therapeutics Submits New Drug Application to U.S. FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression
finance.yahoo.com - April 23 at 8:38 AM
Sage Therapeutics asks FDA to approve lead drug for postpartum depressionSage Therapeutics asks FDA to approve lead drug for postpartum depression
finance.yahoo.com - April 23 at 8:38 AM
Sage Therapeutics down 7% on Biogen/Ionis dealSage Therapeutics down 7% on Biogen/Ionis deal
seekingalpha.com - April 20 at 4:57 PM
Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped TodayWhy Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today
finance.yahoo.com - April 20 at 4:57 PM
Kevin P. Starr Sells 59,000 Shares of SAGE Therapeutics Inc (SAGE) StockKevin P. Starr Sells 59,000 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - April 19 at 7:18 PM
Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical MeetingsSage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
finance.yahoo.com - April 17 at 5:26 PM
SAGE Therapeutics (SAGE) Downgraded by BidaskClubSAGE Therapeutics (SAGE) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM
 Brokerages Anticipate SAGE Therapeutics Inc (SAGE) to Post -$1.85 EPS Brokerages Anticipate SAGE Therapeutics Inc (SAGE) to Post -$1.85 EPS
www.americanbankingnews.com - April 14 at 3:11 PM
Sage takeover rumors unfoundedSage takeover rumors unfounded
seekingalpha.com - April 10 at 5:03 PM
Noteworthy Tuesday Option Activity: DDS, COST, SAGENoteworthy Tuesday Option Activity: DDS, COST, SAGE
www.nasdaq.com - April 10 at 5:03 PM
SAGE Therapeutics (SAGE) Rating Lowered to Sell at BidaskClubSAGE Therapeutics (SAGE) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
SAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from BrokeragesSAGE Therapeutics Inc (SAGE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 3:22 AM
ValuEngine Upgrades SAGE Therapeutics (SAGE) to "Buy"ValuEngine Upgrades SAGE Therapeutics (SAGE) to "Buy"
www.americanbankingnews.com - April 3 at 12:30 AM
SAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.85 Per ShareSAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$1.85 Per Share
www.americanbankingnews.com - March 28 at 5:24 PM
Sage CEO on post-partum depression, innovation for the co...Sage CEO on post-partum depression, innovation for the co...
finance.yahoo.com - March 28 at 4:55 PM
Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug ‘fairly’
finance.yahoo.com - March 28 at 4:55 PM
Canaccord Genuity Analysts Give SAGE Therapeutics (SAGE) a $210.00 Price TargetCanaccord Genuity Analysts Give SAGE Therapeutics (SAGE) a $210.00 Price Target
www.americanbankingnews.com - March 26 at 8:37 AM
SAGE Therapeutics (SAGE) Earns "Buy" Rating from CowenSAGE Therapeutics (SAGE) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - March 20 at 9:22 PM
Corbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head ContrastCorbus Pharmaceuticals (CRBP) vs. SAGE Therapeutics (SAGE) Head-To-Head Contrast
www.americanbankingnews.com - March 18 at 5:20 PM
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage ...
www.prnewswire.com - March 16 at 8:58 AM
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra OncologyPre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology
www.bizjournals.com - March 16 at 8:58 AM
See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.
finance.yahoo.com - March 15 at 5:35 PM

SEC Filings

SAGE Therapeutics (NASDAQ:SAGE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SAGE Therapeutics (NASDAQ:SAGE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SAGE Therapeutics (NASDAQ SAGE) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.